And what, how are local doctors and healthcare experts, addiction experts handling these potential unknowns Chris Serres: , I mean, theres a lot of excitement around this
Figure 2: Novel Incretin Mimetic Assets for T2DM and Obesity in Phase 2/3 of Development Remaining Unmet Needs Remaining Unmet Needs Though the value proposition of on-market GLP-1 and dual-agonists is strong, several key unmet needs still exist for incretin mimetics across diabetes and obesity, namely: (1) improved efficacy, (2) better tolerability, (3) more convenient options / alternative ROAs, and (4) improved access and affordability
Side effects are generally mild and may include temporary redness at the injection site, headache, or nausea
Anadn et al
Blood pressure and metabolic effects of acetyl-L-carnitine in type 2 diabetes: DIABASI randomized controlled trial
Mit dem Erls der Aktivitten untersttzen wir im Landkreis Oldenburg Familien in Not